UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G/A

Under the Securities Exchange Act of 1934 (Amendment No. 1)*

	TScan Therapeutics, Inc. (Name of Issuer)
	(
	Common Stock, par value \$0.0001 per share
	(Title of Class of Securities)
	89854M101
	(CUSIP Number)
	Ofira Kadmor
	Senior VP Finance
	Pitango Venture Capital
	11 HaMenofim St. Bldg. B
	Herzliya 4672562, Israel
	Tel +972-9-971-8100
	(Name, Address and Telephone Number of Person
	Authorized to Receive Notices and Communications)
	December 31, 2023
	(Date of Event which Requires Filing of this Statement)
Check the a	appropriate box to designate the rule pursuant to which this Schedule is filed:
	D 1, 124 1(4)
	Rule 13d-1(b)
	Rule 13d-1(c)
X	Rule 13d-1(d)
*1	The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of
	and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
	he information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities
	Act of 1934, as amended (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of owever, see the Notes).

	111111111111111111111111111111111111111				
	Pitango Heal	thTech Fund I, L.P.			
2.	CHECK THE (see instruction (a) (b) (c)	E APPROPRIATE BOX IF A MEMBER OF A GROUP ons)			
3.	SEC USE O	NLY			
4.	CITIZENSH	IP OR PLACE OF ORGANIZATION			
	Cayman Isla	nds			
		5. SOLE VOTING POWER 2,022,034			
SI BENE	IMBER OF SHARES EFICIALLY WNED BY EACH EPORTING SON WITH	6. SHARED VOTING POWER 0 7. SOLE DISPOSITIVE POWER			
		2,022,034 8. SHARED DISPOSITIVE POWER			
		0			
9.		TE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
10.	2,022,034 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) □				
11.		OF CLASS REPRESENTED BY AMOUNT IN ROW (9)			
12.	4.2% (1) TYPE OF R	EPORTING PERSON (see instructions)			
	PN				
(1)	shares of the	age reflects the percentage of the total number of outstanding shares of the Issuer's common stock. It is calculated based on 47,824,680 e Issuer's common stock, composed of 43,548,092 shares of voting common stock and 4,276,588 shares of non-voting common stock, as of Newton by 2, 2022, as reported by the Issuer is its quarterly report on Form 10.0 filed with the Securities and Evaluates.			

(1) This percentage reflects the percentage of the total number of outstanding shares of the Issuer's common stock. It is calculated based on 47,824,680 shares of the Issuer's common stock, composed of 43,548,092 shares of voting common stock and 4,276,588 shares of non-voting common stock, outstanding as of November 3, 2023, as reported by the Issuer in its quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2023. Since a portion of the Issuer's outstanding common stock is non-voting, the percentage voting power of the entire class of common stock possessed by the Reporting Person's shares is 4.6%.

1	NAMES OF REPORTING PERSONS						
1.	Pitango HealthTech Fund I - Israel L.P.						
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) □ (b) □						
3.	SEC USE ONLY						
4.	CITIZENSHIP OR PLACE OF ORGANIZATION Israel						
NI	5. SOLE VOTING POWER 14,442						
BEN	JMBER OF SHARES 6. SHARED VOTING POWER WHED BY 0 7. SOLE DISPOSITIVE DOWER						
RE	EACH EPORTING RSON WITH 7. SOLE DISPOSITIVE POWER 14,442 8. SHARED DISPOSITIVE POWER						
	8. SHARED DISPOSITIVE POWER 0						
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 14,442						
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) □						
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.03% (1)						
12.	TYPE OF REPORTING PERSON (see instructions) PN						
(1)	This percentage reflects the percentage of the total number of outstanding shares of the Issuer's common stock. It is calculated based on 47,824,680 shares of the Issuer's common stock, composed of 43,548,092 shares of voting common stock and 4,276,588 shares of non-voting common stock, outstanding as of November 3, 2023, as reported by the Issuer in its quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2023. Since a portion of the Issuer's outstanding common stock is non-voting, the percentage voting power of the						

entire class of common stock possessed by the Reporting Person's shares is 0.03%.

0.09% (1)
 TYPE OF REPORTING PERSON (see instructions)
 PN

 This percentage reflects the percentage of the total number of outstanding shares of the Issuer's common stock. It is calculated based on 47,824,680 shares of the Issuer's common stock, composed of 43,548,092 shares of voting common stock and 4,276,588 shares of non-voting common stock, outstanding as of November 3, 2023, as reported by the Issuer in its quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2023. Since a portion of the Issuer's outstanding common stock is non-voting, the percentage voting power of the entire class of common stock possessed by the Reporting Person's shares is 0.1%.

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

10.

11.

(see instructions) \square

1.	NAMES OF R	EPORTING PERSONS
	Pitango H.T. F	fund I, L.P.
3.	CHECK THE (see instruction (a) □ (b) □ SEC USE ON	
4.	CITIZENSHIF	P OR PLACE OF ORGANIZATION
	Cayman Island	ds
		5. SOLE VOTING POWER 0
SI BENE	UMBER OF SHARES NEFICIALLY WNED BY	5. SHARED VOTING POWER 2,079,985 (1)
RI	EACH EPORTING	7. SOLE DISPOSITIVE POWER 0
		3. SHARED DISPOSITIVE POWER 2,079,985 (1)
9.	AGGREGATE 2,079,985 (1)	E AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
10.		HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ns) □
11.		F CLASS REPRESENTED BY AMOUNT IN ROW (9)
12.	4.3% (2) TYPE OF REI	PORTING PERSON (see instructions)
	PN	
(1)	Israel L.P. and	079,985 shares of the Issuer's common stock, held, in the aggregate, by Pitango HealthTech Fund I, L.P., Pitango HealthTech Fund I - d Pitango HealthTech Principals Fund I, L.P., for each of which the Reporting Person serves as sole general partner and therefore red voting and dispositive power with respect to the shares held thereby.
(2)		ge reflects the percentage of the total number of outstanding shares of the Issuer's common stock. It is calculated based on 47,824,680 Issuer's common stock, composed of 43,548,092 shares of voting common stock and 4,276,588 shares of non-voting common stock,

outstanding as of November 3, 2023, as reported by the Issuer in its quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2023. Since a portion of the Issuer's outstanding common stock is non-voting, the percentage voting power of the

entire class of common stock possessed by the shares beneficially owned by the Reporting Person is 4.8%.

Item 1.

- (a) Name of Issuer
- TScan Therapeutics, Inc.
- (b) Address of Issuer's Principal Executive Offices 830 Winter Street, Waltham, Massachusetts 02451

Item 2.

(a) Name of Person Filing:

The following entities are filing this Amendment No. 1 (this "Amendment") to the Statement of Beneficial Ownership on Schedule 13G filed on February 14, 2022 (the "Statement"):

- (i) Pitango HealthTech Fund I, L.P.
- (ii) Pitango HealthTech Fund I Israel L.P.
- (iii) Pitango HealthTech Principals Fund I, L.P.; and
- (iv) Pitango H.T. Fund I, L.P. ("Pitango GP").

Collectively, the entities identified in the foregoing clauses (i)-(iii) are referred to herein as the "Pitango Investing Entities", and, together with Pitango GP, as the "Pitango Reporting Persons".

The Pitango Investing Entities directly hold the shares of common stock (as defined in Item 2(d) below) that are reported in this Amendment. Pitango GP serves as the sole general partner for each of the Pitango Investing Entities, and, consequently, possesses shared voting and dispositive power with respect to all such shares of common stock that are held by the Pitango Investing Entities.

The partners of Pitango GP are two individuals and seven private companies that are each owned by one of the following individuals—Guy Ezekiel, Ittai Harel, Ayal Itzkovitz, Eyal Niv, Isaac Hillel, Rami Kalish, Aaron Mankovski, Chemi Peres and Zeev Binman (the "Pitango Principals"). The Pitango Principals may therefore be deemed to possess shared voting and dispositive power with respect to all shares of common stock held by the Pitango Investing Entities.

(b) Address of the Principal Office or, if none, residence:

The principal business office of each of the Pitango Reporting Persons is: 11 HaMenofim St., Building B, Herzliya, 4672562, Israel

(c) Citizenship

Please see row 4 of the cover pages of the respective Pitango Reporting Persons.

(d) Title of Class of Securities

Common Stock, par value \$0.0001 per share ("common stock")

(e) CUSIP Number

89854M101

Item 3	. If th	is statement is f	iled pursuant t	to §§24	0.13d-1(b) c	or 240.13d	l-2(b) or ((c),	check whether	the person	filing is a	ı
--------	---------	-------------------	-----------------	---------	--------------	------------	-------------	------	---------------	------------	-------------	---

(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(f)		An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);			
(g)		A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);			
(h)		A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);			
(i)		A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);			
(j)		Group, in accordance with §240.13d-1(b)(1)(ii)(J).			
	Not applicable.				

Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount beneficially owned: Please see row 9 of the cover pages of the respective Pitango Reporting Persons.

An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

- (b) Percent of class: Please see row 11 and footnote (1) of the cover pages of the respective Pitango Reporting Persons (in the case of the Pitango GP, footnote (2)). The percentages appearing on the cover pages of the respective Pitango Reporting Persons (and in the last paragraph of this Item 4 below) are calculated based on 47,824,680 shares of common stock, composed of 43,548,092 shares of voting common stock and 4,276,588 shares of non-voting common stock, outstanding as of November 3, 2023, as reported by the Issuer in its quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2023.
- (c) Number of shares as to which the person has:
 - (i) Sole power to vote or to direct the vote: Please see row 5 of the cover pages of the respective Pitango Reporting Persons and the related footnotes on such cover pages.
 - (ii) Shared power to vote or to direct the vote: Please see row 6 of the cover pages of the respective Pitango Reporting Persons and the related footnotes on such cover pages.
 - (iii) Sole power to dispose or to direct the disposition of: Please see row 7 of the cover pages of the respective Pitango Reporting Persons and the related footnotes on such cover pages.
 - (iv) Shared power to dispose or to direct the disposition of: Please see row 8 of the cover pages of the respective Pitango Reporting Persons and the related footnotes on such cover pages.

The Pitango Principals possess shared voting and dispositive power with respect to all shares of common stock held by the Pitango Investing Entities (and beneficially owned by the Pitango Reporting Persons), in the aggregate, and may therefore be deemed to beneficially own an aggregate of 2,079,985 shares of common stock, constituting 4.3% of the number of shares of issued and outstanding common stock and possessing 4.8% of the percentage voting power of the entire class of common stock. Each of the Pitango Principals disclaims beneficial ownership of all such shares except to the extent of his pecuniary interest therein.

Item 5. Ownership of Five Percent or Less of a Class.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

Not applicable.

Item 8. Identification and Classification of Members of the Group.

If a group has filed this schedule pursuant to Rule 13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group.

Not applicable.

Item 9. Notice of Dissolution of Group.

Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. (See Item 5)

Not applicable.

Item 10. Certification.

Not applicable.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

PITANGO HEALTHTECH FUND I, L.P.

By: Pitango H.T. Fund I, L.P., its General Partner By: Pitango GP Health Holdings Ltd., its general partner

By: /s/ Eyal Klein

Name: Eyal Klein

Title: Chief Financial Officer

By: /s/ Ittai Harel

Name: Ittai Harel Title: Managing Director

Date: February 8, 2024

PITANGO HEALTHTECH FUND I - ISRAEL L.P.

By: Pitango H.T. Fund I, L.P., its General Partner By: Pitango GP Health Holdings Ltd., its general partner

By: /s/ Eyal Klein Name: Eyal Klein

Title: Chief Financial Officer

By: /s/ Ittai Harel Name: Ittai Harel Title: Managing Director

Date: February 8, 2024

PITANGO HEALTHTECH PRINCIPALS FUND I, L.P.

By: Pitango H.T. Fund I, L.P., its General Partner By: Pitango GP Health Holdings Ltd., its general partner

By: /s/ Eyal Klein Name: Eyal Klein

Title: Chief Financial Officer

By: /s/ Ittai Harel Name: Ittai Harel Title: Managing Director

Date: February 8, 2024

PITANGO H.T. FUND I, L.P.

By: Pitango GP Health Holdings Ltd., its general partner

By: /s/ Eyal Klein

Name: Eyal Klein

Title: Chief Financial Officer

By: /s/ Ittai Harel

Name: Ittai Harel Title: Managing Director

Date: February 8, 2024

EXHIBITS

Exhibit 1 – Joint Filing Agreement pursuant to Rule 13d-1(k)(1)

Exhibit 1 JOINT FILING AGREEMENT

The undersigned parties hereby agree that this Amendment No. 1 to the Statement of Beneficial Ownership on Schedule 13G filed herewith by the undersigned parties, relating to the common stock, par value \$0.0001 per share of TScan Therapeutics, Inc., is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended, on behalf of each such person.

PITANGO HEALTHTECH FUND I, L.P.

By: Pitango H.T. Fund I, L.P., its General Partner

By: Pitango GP Health Holdings Ltd., its general partner

By: /s/ Eyal Klein

Name: Eyal Klein

Title: Chief Financial Officer

By: /s/ Ittai Harel

Name: Ittai Harel Title: Managing Director

Date: February 8, 2024

PITANGO HEALTHTECH FUND I - ISRAEL L.P.

By: Pitango H.T. Fund I, L.P., its General Partner By: Pitango GP Health Holdings Ltd., its general partner

By: /s/ Eyal Klein Name: Eyal Klein

Title: Chief Financial Officer

By: /s/ Ittai Harel
Name: Ittai Harel

Name: Ittai Harel
Title: Managing Director

Date: February 8, 2024

PITANGO HEALTHTECH PRINCIPALS FUND I, L.P.

By: Pitango H.T. Fund I, L.P., its General Partner By: Pitango GP Health Holdings Ltd., its general partner

By: /s/ Eyal Klein

Name: Eyal Klein

Title: Chief Financial Officer

By: /s/ Ittai Harel

Name: Ittai Harel Title: Managing Director

Date: February 8, 2024

PITANGO H.T. FUND I, L.P.

By: Pitango GP Health Holdings Ltd., its general partner

By: /s/ Eyal Klein Name: Eyal Klein Title: Chief Financial Officer

By: /s/ Ittai Harel

Name: Ittai Harel Title: Managing Director

Date: February 8, 2024